Table 1.
Baseline characteristics of patients in the RAPID 1, 2 (ITT populations) and FAST4WARD (modified ITT population) trials [4–6]
| Baseline characteristics | RAPID 1 (n = 982) | RAPID 2 (n = 619) | FAST4WARD (n = 220) |
|---|---|---|---|
| Age, mean (s.d.), years | 52.0 (11.6) | 51.9 (11.5) | 53.8 (12.2) |
| Sex, female, % | 83.2 | 81.6 | 83.6 |
| Duration of RA, mean (s.d.), years | 6.1 (4.3) | 6.2 (4.2) | 9.5 (8.9) |
| No. of previous DMARDs, mean (s.d.) | 2.3 (1.3) | 2.2 (1.3) | 2.0 (1.2) |
| MTX dose, mean, mg/week | 13.6 | 12.5 | NA |
| RF positive, ≥14 IU/ml, % | 81.8 | 76.9 | 100 |
| Tender joint count, mean (s.d.) | 30.7 (12.9) | 30.2 (14.0) | 29.0 (13.1) |
| Swollen joint count, mean (s.d.) | 21.5 (9.8) | 21.0 (9.8) | 20.5 (9.7) |
| Patient’s assessment of arthritis pain (0–100 mm VAS), mean (s.d.) | 63.1 (18.9) | 60.9 (20.2) | 56.5 (21.4) |
| HAQ-DI, mean (s.d.) | 1.7 (0.6) | 1.6 (0.6) | 1.5 (0.6) |
| DAS-28 (ESR), mean (s.d.) | 6.9 (0.8) | 6.8 (0.8) | 6.3 (1.0) |
| CRP, geometric mean (CV), mg/l | 14.7 (144.2) | 13.6 (180.9) | 11.5 (233.1) |
| FAS (0–10), mean (s.d.) | 6.5 (2.0) | 6.5 (1.9) | 6.3 (2.2) |
| SF-36 PCS, mean (s.d.) | 30.8 (6.5) | 30.9 (6.2) | 27.9 (7.8) |
| SF-36 MCS, mean (s.d.) | 39.4 (11.2) | 39.3 (11.0) | 44.7 (11.5) |
The ITT populations for RAPID 1 and 2 consisted of all patients who were randomized into the studies; the modified ITT population for FAST4WARD consisted of all randomized patients who had taken one or more dose of study medication. Adapted from Mease [21] with permission of Future Medicine Ltd. CV: coefficient of variation; ITT: intention-to-treat; NA: not applicable.